CCNU in the Treatment of Canine Epitheliotropic Lymphoma
Article first published online: 28 JUN 2008
© 2006 American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 20, Issue 1, pages 136–143, January 2006
How to Cite
Williams, L. E., Rassnick, K. M., Power, H. T., Lana, S. E., Morrison-Collister, K. E., Hansen, K. and Johnson, J. L. (2006), CCNU in the Treatment of Canine Epitheliotropic Lymphoma. Journal of Veterinary Internal Medicine, 20: 136–143. doi: 10.1111/j.1939-1676.2006.tb02833.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Revised January 7, 2005; Accepted June 30, 2005.
- Mycosis fungoides
This retrospective study examined the use of CCNU (1-[2-chloroethyl]3-cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86%) dogs had the cutaneous form of disease, and 5 (14%) dogs had the oral form of disease. Nineteen (51%) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m2 (range, 50–100 mg/m2). The median number of treatments administered was 3 (range, 1–12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35%) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78%) dogs had a measurable response to CCNU for a median duration of 106 days (95% confidence interval [CI], 75–182). Six dogs (17%) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61%) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95% CI, 62–170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29% of the dogs, gastrointestinal signs in up to 22% of the dogs, and liver enzyme activity increases in up to 86% of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.